

## Anti-TNFRSF10B/TRAILR2/CD262 Antibody (Lexatumumab)

### Introduction

Lexatumumab (HGS-ETR 2) is a human IgG1 monoclonal antibody that agonizes TRAIL receptor 2 (TRAIL-R2, DR5, APO-2). Lexatumumab induces apoptosis in malignant mesothelioma. Lexatumumab can be used in the study of malignant pleural mesothelioma (MPM).

### Product parameters

Alternative Names	ETR2-ST01, HGS-ETR2, HGS1018
Target Accession	O14763
Target	TNFRSF10B / TRAILR2 / CD262
CAS number	845816-02-6
Molecular Weight	143.48 kDa
Host	CHO
Reactivity	Human, Mouse
Conjugation	Unconjugated
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG1
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	Immobilized human TNFRSF10B/TRAILR2 / CD262, Fc Tag at 2 ug/mL can bind lexatumumab, EC50=0.03685 ug/mL.
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 µM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

## Note

1. This product is for scientific research use only.



### **APExBIO Technology**

**[www.apexbt.com](http://www.apexbt.com)**

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: [info@apexbt.com](mailto:info@apexbt.com)

